Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06679985 · ClinicalTrials.gov registry record · Phase 2
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
A Phase 2 study of Hepatocellular Carcinoma, sponsored by Coherus Oncology.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 20
- Study locations
NCT06679985: Recruiting Phase 2 study of Hepatocellular Carcinoma, sponsored by Coherus Oncology.
NCT06679985 is a Phase 2 study of Hepatocellular Carcinoma that is actively recruiting participants, run by Coherus Oncology. The registered enrollment target is 72 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06679985, a Phase 2 study of Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Coherus Oncology.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Toripalimab
- DRUG Casdozokitug
Study Locations (20)
California
- Beverly Hills Cancer Center - Beverly Hills
- City of Hope - Duarte
- City of Hope at Irvine Lennar - Irvine
- Cancer & Blood Specialty Clinic - Lakewood
- USC Norris Comprehensive Cancer Center - Los Angeles
- Sarcoma Oncology Center - Santa Monica
Arizona
- Mayo Clinic - Scottsdale - Scottsdale
- University of Arizona - Cancer Center - Tucson
New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center - New York
- Montefiore Medical Center - The Bronx
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James) - Columbus
Florida
- Mayo Clinic - Jacksonville - Jacksonville
Georgia
- The Winship Cancer Institute Emory University - Atlanta
Idaho
- Mountain States Tumor Institute at St. Luke's Regional Medical Center - Boise
Kansas
- University of Kansas Cancer Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2024-12-20 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
What NCT06679985 shows while recruiting
NCT06679985 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT06679985 names 20 study sites across 12 states, led by California, Arizona, New York.
Frequently Asked Questions
What is clinical trial NCT06679985 about?
NCT06679985 is a clinical study titled "A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma". The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.
What is the current status of trial NCT06679985?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2024-12-20. Estimated completion is 2027-09.
What conditions does trial NCT06679985 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT06679985?
The interventions under investigation include: Bevacizumab (DRUG), Toripalimab (DRUG), Casdozokitug (DRUG).
Who is sponsoring clinical trial NCT06679985?
This trial is sponsored by Coherus Oncology, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06679985 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06679985's enrollment target sits among peer trials
72 70th of 145 higher than 75 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI